Completes $650M AZSTARYS Acquisition, Raises 2026 Guidance, and Announces Executive Departures
COLL sits 29% above its 52-week low of $27.84.
Summary
Collegium Pharmaceutical completed its $650 million acquisition of AZSTARYS, leading to a significant increase in its 2026 financial guidance, despite the simultaneous announcement of two executive departures.
Key Events · M&A and Partnerships · COLL
-
AZSTARYS Acquisition Completed
The company finalized the previously announced $650 million acquisition of AZSTARYS, a central nervous system stimulant for ADHD, from Corium Therapeutics. The deal was funded by $350 million in existing cash and a $300 million delayed draw term loan, with potential for up to $135 million in additional milestone payments.
-
2026 Financial Guidance Raised
Collegium Pharmaceutical increased its full-year 2026 total product revenues guidance to a range of $865-$895 million (up from $805-$825 million) and Adjusted EBITDA guidance to $475-$500 million (up from $455-$475 million), reflecting the anticipated impact of the AZSTARYS acquisition.
-
New Inducement Equity Plan Adopted
The Board adopted a 2026 Inducement Plan, authorizing the grant of equity awards for up to 325,000 shares of common stock to new employees. This authorization represents approximately 1% of the company's current market capitalization.
-
Executive Leadership Departures Announced
Executive Vice President and Chief Commercial Officer Scott Dreyer will depart effective August 30, 2026, and Executive Vice President and Chief Medical Officer Thomas Smith, M.D., will depart following a transition period. Both departures are treated as terminations without cause.
Analysis · COLL · Life Sciences
Collegium Pharmaceutical has finalized its significant $650 million acquisition of AZSTARYS, a key ADHD treatment, which was previously announced. This completion is highly important as it immediately translates into a substantial increase in the company's 2026 financial guidance for both revenue and Adjusted EBITDA, solidifying a major strategic expansion. While the departure of two Executive Vice Presidents introduces some leadership uncertainty, the positive financial impact and strategic alignment from the acquisition are the dominant market-moving factors.
At the time of this filing, COLL was trading at $35.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $27.84 to $50.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.